BioMarin is a global biotechnology company focused on developing therapies for rare genetic conditions. Founded in 1997, the company operates in more than 70 countries and has approximately 3,000 employees. Its work centers on areas including genetics, molecular biology, enzyme replacement therapies, and gene therapy.
The company has nine approved therapies for rare genetic conditions. Its research and development efforts are directed at serious and often life-limiting diseases with limited treatment options. BioMarin's team culture is described as collaborative and purpose-driven, focused on pursuing genetic discoveries.
